S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

SOPHiA Genetics Stock Forecast, Price & News

-0.69 (-4.94%)
(As of 12/1/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
69,303 shs
Average Volume
98,775 shs
Market Capitalization
$841.76 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SOPH News and Ratings via Email

Sign-up to receive the latest news and ratings for SOPHiA Genetics and its competitors with MarketBeat's FREE daily newsletter.

SOPHiA Genetics logo

About SOPHiA Genetics

SOPHiA GENETICS SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM(TM) Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. SOPHiA GENETICS SA is based in BOSTON.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$28.40 million
Book Value
$4.57 per share


Net Income
$-39.34 million
Net Margins
Pretax Margin




Free Float
Market Cap
$841.76 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.70 out of 5 stars

Medical Sector

927th out of 1,392 stocks

Biological Products, Except Diagnostic Industry

140th out of 202 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

SOPHiA Genetics (NASDAQ:SOPH) Frequently Asked Questions

Is SOPHiA Genetics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SOPHiA Genetics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SOPHiA Genetics stock.
View analyst ratings for SOPHiA Genetics
or view top-rated stocks.

When is SOPHiA Genetics' next earnings date?

SOPHiA Genetics is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for SOPHiA Genetics

How were SOPHiA Genetics' earnings last quarter?

SOPHiA Genetics SA (NASDAQ:SOPH) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.38) by $0.08. The business had revenue of $10.36 million for the quarter, compared to analyst estimates of $10.25 million. SOPHiA Genetics had a negative trailing twelve-month return on equity of 44.62% and a negative net margin of 168.10%.
View SOPHiA Genetics' earnings history

What guidance has SOPHiA Genetics issued on next quarter's earnings?

SOPHiA Genetics issued an update on its FY 2021 earnings guidance on Wednesday, December, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $40 M-, compared to the consensus revenue estimate of $40.14 million.

What price target have analysts set for SOPH?

4 brokerages have issued 1-year price objectives for SOPHiA Genetics' stock. Their forecasts range from $22.00 to $24.00. On average, they anticipate SOPHiA Genetics' share price to reach $23.00 in the next year. This suggests a possible upside of 73.1% from the stock's current price.
View analysts' price targets for SOPHiA Genetics
or view top-rated stocks among Wall Street analysts.

When did SOPHiA Genetics IPO?

(SOPH) raised $234 million in an IPO on Friday, July 23rd 2021. The company issued 13,000,000 shares at a price of $17.00-$19.00 per share.

What is SOPHiA Genetics' stock symbol?

SOPHiA Genetics trades on the NASDAQ under the ticker symbol "SOPH."

When does the company's lock-up period expire?

SOPHiA Genetics' lock-up period expires on Wednesday, January 19th. SOPHiA Genetics had issued 13,000,000 shares in its initial public offering on July 23rd. The total size of the offering was $234,000,000 based on an initial share price of $18.00. After the end of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are SOPHiA Genetics' major shareholders?

SOPHiA Genetics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Generation Investment Management LLP (10.72%), Credit Suisse AG (2.97%), Principal Financial Group Inc. (1.30%), Jennison Associates LLC (1.02%), Pura Vida Investments LLC (0.71%) and Millennium Management LLC (0.50%).

Which major investors are buying SOPHiA Genetics stock?

SOPH stock was acquired by a variety of institutional investors in the last quarter, including Generation Investment Management LLP, Credit Suisse AG, Principal Financial Group Inc., Jennison Associates LLC, Pura Vida Investments LLC, Millennium Management LLC, BlackRock Inc., and RTW Investments LP.

How do I buy shares of SOPHiA Genetics?

Shares of SOPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SOPHiA Genetics' stock price today?

One share of SOPH stock can currently be purchased for approximately $13.29.

How much money does SOPHiA Genetics make?

SOPHiA Genetics has a market capitalization of $841.76 million and generates $28.40 million in revenue each year.

What is SOPHiA Genetics' official website?

The official website for SOPHiA Genetics is www.sophiagenetics.com.

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.